Again, maybe I'm not the best person to answer that. An overly simplistic answer might be that there's just not the incentive there. There aren't enough children being diagnosed with drug-resistant TB in order for a pharmaceutical company to say, “Let's invest in making a child-friendly formulation.”
On March 24th, 2014. See this statement in context.